Prostate Cancer — Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
Citation(s)
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study)